Cargando…

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes

This is an editorial about non‐invasive fibrosis markers in patients with NASH and type 2 diabetes mellitus.[Image: see text]

Detalles Bibliográficos
Autores principales:	Fan, Weiguo, Torok, Natalie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034576/ https://www.ncbi.nlm.nih.gov/pubmed/33860113 http://dx.doi.org/10.1002/hep4.1662

Ejemplares similares

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness
por: Indira Chandran, Vineesh, et al.
Publicado: (2023)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

TRIF as a Novel Modulator of Liver Inflammation and Fibrosis
por: Török, Natalie J.
Publicado: (2017)

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
por: Luo, Yi, et al.
Publicado: (2021)

NASH: Connecting the dots with patients in mind
por: Cryer, Donna R.
Publicado: (2020)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C
por: Ladero, Jose M.
Publicado: (2011)

Advancing proteomics and machine learning in the clinic: an editorial on “Noninvasive proteomic biomarkers for alcohol-related liver disease”
por: McGinnis, Courtney D., et al.
Publicado: (2022)

Editorial: Immune mechanisms of inflammation in NASH
por: Hirsova, Petra, et al.
Publicado: (2022)

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
por: Kozumi, Kazuhiro, et al.
Publicado: (2021)

Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis
por: Kar, Sumit, et al.
Publicado: (2019)

DNA methylation of SMPD3-based diagnostic biomarkers of NASH and mild fibrosis
por: Wu, Na, et al.
Publicado: (2023)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

A Molecular Signature of Mouse NASH: A Step Closer to a Human Predictive Biomarker?
por: Ibrahim, Samar H., et al.
Publicado: (2017)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Letter from Dr. Nash
por: Hart, James A.
Publicado: (1875)

Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging
por: Li, Yuan, et al.
Publicado: (2022)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
por: Brown, Elizabeth A., et al.
Publicado: (2023)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

NASH and Systemic Complications: From Basic to Clinical Research
por: Baumgartner, Sabine, et al.
Publicado: (2021)

NASH‐related cirrhosis: An occult liver disease burden
por: Arrese, Marco, et al.
Publicado: (2017)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
por: van Koppen, Arianne, et al.
Publicado: (2017)

NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease
por: Manka, Paul, et al.
Publicado: (2020)

Potential role of noninvasive biomarkers during liver fibrosis
por: Kaur, Navneet, et al.
Publicado: (2021)

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
por: Pearce, Steven G, et al.
Publicado: (2013)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Production, Exacerbating Effect, and EV-Mediated Transcription of Hepatic CCN2 in NASH: Implications for Diagnosis and Therapy of NASH Fibrosis
por: Li, Xinlei, et al.
Publicado: (2023)

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
por: Reinson, Tina, et al.
Publicado: (2023)

Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?
por: Tarantino, Giovanni
Publicado: (2013)

NRF2 Induction for NASH Treatment: A New Hope Rises
por: Rojo de la Vega, Montserrat, et al.
Publicado: (2018)

Osr1 Is a Critical Regulator of Macrophage Polarization in NASH Progression
por: Lee, Jin, et al.
Publicado: (2023)

A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease
por: Liang, Jing, et al.
Publicado: (2017)

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
por: Huisman, Tsipora M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kelfs2v8q8evk96o7bfd0kaork